<DOC>
	<DOCNO>NCT00298363</DOCNO>
	<brief_summary>This study design evaluate compare safety tolerability tenofovir disoproxil fumarate ( TDF ) , emtricitabine ( FTC ) /TDF , entecavir ( ETV ) treatment hepatitis B patient decompensated liver disease . Safety assess evaluate adverse event ( AEs ) laboratory abnormality . Efficacy assess evaluate reduction Child-Pugh-Turcotte ( CPT ) Model End Stage Liver Disease ( MELD ) score , reduction hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) , change liver enzymes , development drug-resistant mutation , generation antibody virus . A maximum randomized treatment duration 168 week plan . Since subject decompensated liver disease enrol study , necessary provide early intervention strategy profound viral suppression expeditiously achieve . For reason , subject decrease plasma HBV DNA baseline &lt; 2 log_10 copies/mL plasma HBV DNA &gt; 10,000 copies/mL ( plasma HBV DNA &gt; 1,000 copies/mL subject enter study HBV DNA &lt; 10,000 copies/mL ) Week 8 option start open-label FTC/TDF continue study . Subjects virologic breakthrough plasma HBV DNA level remain &gt; 400 copies/mL ( confirm ) 24 week treatment could unblinded investigator 's discretion selection alternative anti-HBV therapy may include open-label FTC/TDF . If study drug permanently discontinue , immediate initiation another anti-HBV regimen strongly recommend .</brief_summary>
	<brief_title>Study Comparing Tenofovir Disoproxil Fumarate ( TDF ) , Emtricitabine ( FTC ) /TDF , Entecavir ( ETV ) Treatment Chronic HBV Subjects With Decompensated Liver Disease .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>A participant require meet follow inclusion criterion eligible participation study : Chronic Hepatitis B infection 18 69 year age , inclusive HBV DNA ≥ 1000 copies/mL Decompensated liver disease follow : CPT score 712 ( inclusive ) OR history CPT score ≥ 7 CPT screen ≤ 12 Serum alanine aminotransferase ( ALT ) &lt; 10 x upper limit normal range ( ULN ) Hemoglobin ≥ 7.5 g/dL Total white blood cell ( WBC ) count ≥ 1,500/mm^3 Platelet count ≥ 30,000/mm^3 Alphafetoprotein ≤ 20 ng/mL ultrasound image evidence hepatocellular carcinoma ( HCC ) , alphafetoprotein 2150 ng/mL compute tomography ( CT ) /magnetic resonance imaging ( MRI ) scan evidence HCC , within 6 month screen Calculated creatinine clearance ≥ 50 mL/min Negative human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) serologies Less 24 month total prior adefovir dipivoxil exposure Willing able provide write informed consent A participant meet follow exclusion criterion could enrol study : Pregnant woman , woman breastfeed believe may wish become pregnant course study Males females reproductive potential unwilling use effective method contraception study Prior use TDF ETV History variceal bleeding , hepatorenal syndrome , Grade 3 4 hepatic encephalopathy , spontaneous bacterial peritonitis within 60 day screen Grade 2 hepatic encephalopathy screen History solid organ bone marrow transplant Current use hepatotoxic drug , nephrotoxic drug , drug interfere renal tubular secretion Current therapy immunomodulators ( eg , corticosteroid , interleukin2 , etc . ) investigational drug Diagnosis proximal tubulopathy Use investigational agent within 30 day prior screen Known hypersensitivity TDF , FTC , ETV , formulation excipients study drug product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatitis ; Hepatitis B virus ; Tenofovir</keyword>
</DOC>